Published in Oncogene on November 24, 2008
Human papillomavirus oncoproteins: pathways to transformation. Nat Rev Cancer (2010) 4.99
Cancer associated human papillomaviruses. Curr Opin Virol (2012) 1.25
Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses. Virology (2012) 1.23
Cell polarity proteins: common targets for tumorigenic human viruses. Oncogene (2008) 1.22
Structural basis for hijacking of cellular LxxLL motifs by papillomavirus E6 oncoproteins. Science (2013) 1.22
Distinct functions of HTLV-1 Tax1 from HTLV-2 Tax2 contribute key roles to viral pathogenesis. Retrovirology (2009) 1.21
Emerging theme: cellular PDZ proteins as common targets of pathogenic viruses. J Virol (2011) 1.12
Tetraspanin CD151 mediates papillomavirus type 16 endocytosis. J Virol (2013) 1.11
Putative mechanisms of antitumor activity of cyano-substituted heteroaryles in HeLa cells. Invest New Drugs (2010) 1.05
The SARS coronavirus E protein interacts with PALS1 and alters tight junction formation and epithelial morphogenesis. Mol Biol Cell (2010) 1.01
Human papillomavirus type 16 E6 and E7 oncoproteins act synergistically to cause head and neck cancer in mice. Virology (2010) 1.00
Productive Lifecycle of Human Papillomaviruses that Depends Upon Squamous Epithelial Differentiation. Front Microbiol (2012) 0.98
High-risk human papillomavirus E6 oncoproteins interact with 14-3-3ζ in a PDZ binding motif-dependent manner. J Virol (2012) 0.96
Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. J Virol (2012) 0.95
The human PDZome: a gateway to PSD95-Disc large-zonula occludens (PDZ)-mediated functions. Mol Cell Proteomics (2013) 0.94
The invasive capacity of HPV transformed cells requires the hDlg-dependent enhancement of SGEF/RhoG activity. PLoS Pathog (2012) 0.92
PDZD8 is a novel Gag-interacting factor that promotes retroviral infection. J Virol (2010) 0.91
Human tumour viruses and the deregulation of cell polarity in cancer. Nat Rev Cancer (2012) 0.90
E6 and E7 from human papillomavirus type 16 cooperate to target the PDZ protein Na/H exchange regulatory factor 1. J Virol (2011) 0.90
Induction of p53, p21 and apoptosis by silencing the NF90/NF45 complex in human papilloma virus-transformed cervical carcinoma cells. Oncogene (2012) 0.89
The human adenovirus E4-ORF1 protein subverts discs large 1 to mediate membrane recruitment and dysregulation of phosphatidylinositol 3-kinase. PLoS Pathog (2014) 0.88
Aptamer-based therapeutics: new approaches to combat human viral diseases. Pharmaceuticals (Basel) (2013) 0.86
PDZ domains and viral infection: versatile potentials of HPV-PDZ interactions in relation to malignancy. Biomed Res Int (2013) 0.86
Regulation of the human papillomavirus type 18 E6/E6AP ubiquitin ligase complex by the HECT domain-containing protein EDD. J Virol (2011) 0.85
Differential regulation of cell-cell contact, invasion and anoikis by hScrib and hDlg in keratinocytes. PLoS One (2012) 0.85
Biophysical characterization of the complex between human papillomavirus E6 protein and synapse-associated protein 97. J Biol Chem (2010) 0.85
Evolution of human papillomavirus carcinogenicity. Adv Virus Res (2010) 0.83
BMI-1 autoantibody as a new potential biomarker for cervical carcinoma. PLoS One (2011) 0.83
Mechanisms of decreased expression of transforming growth factor-beta receptor type I at late stages of HPV16-mediated transformation. Cancer Lett (2009) 0.82
Structural insights into a wildtype domain of the oncoprotein E6 and its interaction with a PDZ domain. PLoS One (2013) 0.82
Cervical cancer stem cells: opportunities and challenges. J Cancer Res Clin Oncol (2015) 0.81
A novel interaction between hScrib and PP1γ downregulates ERK signaling and suppresses oncogene-induced cell transformation. PLoS One (2013) 0.81
Overexpression of ANXA1 in penile carcinomas positive for high-risk HPVs. PLoS One (2013) 0.80
Functional Roles of E6 and E7 Oncoproteins in HPV-Induced Malignancies at Diverse Anatomical Sites. Cancers (Basel) (2016) 0.79
Targeting the Two Oncogenic Functional Sites of the HPV E6 Oncoprotein with a High-Affinity Bivalent Ligand. Angew Chem Int Ed Engl (2015) 0.79
The mechanism and implications of hScrib regulation of ERK. Small GTPases (2010) 0.79
Targeting the human papillomavirus E6 and E7 oncogenes through expression of the bovine papillomavirus type 1 E2 protein stimulates cellular motility. J Virol (2011) 0.79
Improved affinity at the cost of decreased specificity: a recurring theme in PDZ-peptide interactions. Sci Rep (2016) 0.79
Human papillomavirus infections: warts or cancer? Cold Spring Harb Perspect Biol (2013) 0.78
HIV-1 Vpr induces the degradation of ZIP and sZIP, adaptors of the NuRD chromatin remodeling complex, by hijacking DCAF1/VprBP. PLoS One (2013) 0.78
Degradation of Human PDZ-Proteins by Human Alphapapillomaviruses Represents an Evolutionary Adaptation to a Novel Cellular Niche. PLoS Pathog (2015) 0.78
Possible Human Papillomavirus 38 Contamination of Endometrial Cancer RNA Sequencing Samples in The Cancer Genome Atlas Database. J Virol (2015) 0.77
A novel intracellular antibody against the E6 oncoprotein impairs growth of human papillomavirus 16-positive tumor cells in mouse models. Oncotarget (2016) 0.77
HPV-16 impairs the subcellular distribution and levels of expression of protein phosphatase 1γ in cervical malignancy. BMC Cancer (2015) 0.76
Analysis of Multiple HPV E6 PDZ Interactions Defines Type-Specific PDZ Fingerprints That Predict Oncogenic Potential. PLoS Pathog (2016) 0.76
DNA damage response is hijacked by human papillomaviruses to complete their life cycle. J Zhejiang Univ Sci B (2017) 0.75
Genetic variability in E6, E7 and L1 genes of Human Papillomavirus 62 and its prevalence in Mexico. Infect Agent Cancer (2017) 0.75
The VPS4 component of the ESCRT machinery plays an essential role in HPV infectious entry and capsid disassembly. Sci Rep (2017) 0.75
miR-2861 acts as a tumor suppressor via targeting EGFR/AKT2/CCND1 pathway in cervical cancer induced by human papillomavirus virus 16 E6. Sci Rep (2016) 0.75
E6 and E7 Gene Polymorphisms in Human Papillomavirus Types-58 and 33 Identified in Southwest China. PLoS One (2017) 0.75
Identification of host transcriptional networks showing concentration-dependent regulation by HPV16 E6 and E7 proteins in basal cervical squamous epithelial cells. Sci Rep (2016) 0.75
MiR-23b controls ALDH1A1 expression in cervical cancer stem cells. BMC Cancer (2017) 0.75
Nip the HPV encoded evil in the cancer bud: HPV reshapes TRAILs and signaling landscapes. Cancer Cell Int (2013) 0.75
Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature (1998) 6.16
Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression. Eur J Biochem (1986) 4.80
Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J (1987) 3.81
Comparison of the in vitro transforming activities of human papillomavirus types. EMBO J (1988) 3.81
Two polymorphic variants of wild-type p53 differ biochemically and biologically. Mol Cell Biol (1999) 3.35
Primary structure polymorphism at amino acid residue 72 of human p53. Mol Cell Biol (1987) 3.22
The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene (2001) 2.77
Isolation and characterization of a human p53 cDNA clone: expression of the human p53 gene. EMBO J (1984) 2.45
Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. EMBO J (1982) 2.29
Oncogenic human papillomavirus E6 proteins target the discs large tumour suppressor for proteasome-mediated degradation. Oncogene (1999) 2.25
Interactions of the PDZ-protein MAGI-1 with adenovirus E4-ORF1 and high-risk papillomavirus E6 oncoproteins. Oncogene (2000) 2.20
Detection of novel splicing patterns in a HPV16-containing keratinocyte cell line. Virology (1990) 2.17
The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene (1999) 2.11
High-resolution characterization of herpes simplex virus type 1 transcripts encoding alkaline exonuclease and a 50,000-dalton protein tentatively identified as a capsid protein. J Virol (1983) 2.07
Role of Bak in UV-induced apoptosis in skin cancer and abrogation by HPV E6 proteins. Genes Dev (2000) 2.01
Multi-PDZ domain protein MUPP1 is a cellular target for both adenovirus E4-ORF1 and high-risk papillomavirus type 18 E6 oncoproteins. J Virol (2000) 1.97
Modulation of type M2 pyruvate kinase activity by the human papillomavirus type 16 E7 oncoprotein. Proc Natl Acad Sci U S A (1999) 1.93
Analysis of human p53 proteins and mRNA levels in normal and transformed cells. Eur J Biochem (1986) 1.91
Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transformed by HPV-16 plus EJ-ras. EMBO J (1989) 1.84
Inhibition of Bak-induced apoptosis by HPV-18 E6. Oncogene (1998) 1.78
HPV E6 and MAGUK protein interactions: determination of the molecular basis for specific protein recognition and degradation. Oncogene (2001) 1.78
Identification of human papillomavirus type 18 E6 polypeptide in cells derived from human cervical carcinomas. J Gen Virol (1987) 1.78
Human papillomavirus type 16 E5 gene stimulates the transforming activity of the epidermal growth factor receptor. Oncogene (1992) 1.76
The E5 gene from human papillomavirus type 16 is an oncogene which enhances growth factor-mediated signal transduction to the nucleus. Oncogene (1992) 1.68
E3-ubiquitin ligase/E6-AP links multicopy maintenance protein 7 to the ubiquitination pathway by a novel motif, the L2G box. J Biol Chem (1998) 1.45
Herpes simplex virus non-structural proteins. IV. Purification of the virus-induced deoxyribonuclease and characterization of the enzyme using monoclonal antibodies. J Gen Virol (1983) 1.44
Chemokines regulate IL-6 and IL-8 production by fibroblast-like synoviocytes from patients with rheumatoid arthritis. J Immunol (2001) 1.43
Homozygous c.14576G>A variant of RNF213 predicts early-onset and severe form of moyamoya disease. Neurology (2012) 1.42
Diagnostic iodised oil embolisation of liver tumours--the Hammersmith experience. Eur J Radiol (1993) 1.38
Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J (1994) 1.37
Human papillomavirus (HPV) E6 interactions with Bak are conserved amongst E6 proteins from high and low risk HPV types. J Gen Virol (1999) 1.32
Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer (2010) 1.31
The human papillomavirus type 16 E5 gene cooperates with the E7 gene to stimulate proliferation of primary cells and increases viral gene expression. Virology (1994) 1.27
Serum IgG subclass concentrations in healthy subjects at different age: age normal percentile charts. Eur J Pediatr (1989) 1.25
Attitudes of Asian patients in Birmingham to general practitioner services. J R Coll Gen Pract (1985) 1.24
Mutational analysis of HPV-18 E6 identifies domains required for p53 degradation in vitro, abolition of p53 transactivation in vivo and immortalisation of primary BMK cells. Oncogene (1994) 1.22
HPV E6 degradation of p53 and PDZ containing substrates in an E6AP null background. Oncogene (2007) 1.21
HPV E6 targeted degradation of the discs large protein: evidence for the involvement of a novel ubiquitin ligase. Oncogene (2000) 1.21
The cell polarity regulator hScrib controls ERK activation through a KIM site-dependent interaction. Oncogene (2010) 1.19
Human papillomavirus type 16 E7 binds to the conserved carboxy-terminal region of the TATA box binding protein and this contributes to E7 transforming activity. J Gen Virol (1997) 1.18
The human papillomavirus (HPV)-6 and HPV-16 E5 proteins co-operate with HPV-16 E7 in the transformation of primary rodent cells. J Gen Virol (1995) 1.16
Neuroferritinopathy in a Japanese family with a duplication in the ferritin light chain gene. Neurology (2008) 1.16
HPV-18 E6*I protein modulates the E6-directed degradation of p53 by binding to full-length HPV-18 E6. Oncogene (1999) 1.12
Alternatively spliced HPV-18 E6* protein inhibits E6 mediated degradation of p53 and suppresses transformed cell growth. Oncogene (1997) 1.11
Human and primate tumour viruses use PDZ binding as an evolutionarily conserved mechanism of targeting cell polarity regulators. Oncogene (2008) 1.10
DNA damage induced p53 mediated transcription is inhibited by human papillomavirus type 18 E6. Oncogene (1994) 1.07
Prolactin studies in "functionless" pituitary tumours. Br Med J (1975) 1.07
Differential regulation of human papillomavirus E6 by protein kinase A: conditional degradation of human discs large protein by oncogenic E6. Oncogene (2000) 1.05
Transformation of primary human fibroblast cells with human papillomavirus type 16 DNA and EJ-ras. Int J Cancer (1988) 1.05
Phylogenetic relationships of Eurasian pines (Pinus, Pinaceae) based on chloroplast rbcL, MATK, RPL20-RPS18 spacer, and TRNV intron sequences. Am J Bot (1999) 1.03
Deficiency in mitochondrial aldehyde dehydrogenase increases the risk for late-onset Alzheimer's disease in the Japanese population. Biochem Biophys Res Commun (2000) 1.02
Interaction between the HPV-16 E2 transcriptional activator and p53. Oncogene (1999) 1.02
Induction of apoptosis by p53 is independent of its oligomeric state and can be abolished by HPV-18 E6 through ubiquitin mediated degradation. Oncogene (1996) 1.01
Human papillomavirus type 16 E6 gene cooperates with EJ-ras to immortalize primary mouse cells. Oncogene (1993) 1.00
Allosteric activation of acid alpha-glucosidase by the human papillomavirus E7 protein. J Biol Chem (2000) 1.00
HPV-18 E6 inhibits p53 DNA binding activity regardless of the oligomeric state of p53 or the exact p53 recognition sequence. Oncogene (1996) 0.99
Antiviral traditional medicines against herpes simplex virus (HSV-1), poliovirus, and measles virus in vitro and their therapeutic efficacies for HSV-1 infection in mice. Antiviral Res (1993) 0.99
Anti-sense phosphorothioate oligonucleotides have both specific and non-specific effects on cells containing human papillomavirus type 16. Nucleic Acids Res (1991) 0.97
Alternative splicing of human p53 transcripts. Oncogene Res (1987) 0.97
Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization. J Gen Virol (1987) 0.97
Accumulation of somatic mutation in mitochondrial DNA extracted from peripheral blood cells in diabetic patients. Diabetologia (2002) 0.96
HPV-16 E7 and adenovirus E1a complex formation with TATA box binding protein is enhanced by casein kinase II phosphorylation. Oncogene (1996) 0.94
Children's ability to make probability estimates: skills revealed through application of Anderson's functional measurement methodology. Child Dev (1989) 0.94
Inhibition of E6 induced degradation of p53 is not sufficient for stabilization of p53 protein in cervical tumour derived cell lines. Oncogene (1999) 0.94
Expression analysis of ESts derived from the inner bark of Cryptomeria japonica. Plant Mol Biol (2000) 0.94
Analysis of human papillomavirus sequences in cell lines recently derived from cervical cancers. Cancer Res (1988) 0.92
Proteasome-mediated regulation of the hDlg tumour suppressor protein. J Cell Sci (2001) 0.92
HPV-18 E6 mediated inhibition of p53 DNA binding activity is independent of E6 induced degradation. Oncogene (1995) 0.92
Repression of p53 transcriptional activity by the HPV E7 proteins. Virology (1997) 0.92
The HPV-16 E7 oncoprotein binds Skip and suppresses its transcriptional activity. Oncogene (2001) 0.91
Hoxb8 regulates expression of microRNAs to control cell death and differentiation. Cell Death Differ (2013) 0.91
Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer (2011) 0.91